Colorectal Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Colorectal Cancer – Pipeline Review, H1 2020’, provides an overview of the Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer

– The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4D Pharma Plc

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

A2 Biotherapeutics Inc

Aadi Bioscience Inc

AB Science SA

AbbVie Inc

AbClon Inc

Abcuro Inc

ABM Therapeutics Inc

Abpro Corp

Aclaris Therapeutics Inc

Acrotech Biopharma LLC

Adamed Sp zoo

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

ADT Pharmaceuticals Inc

Aduro BioTech Inc

Advanced BioDesign

Advaxis Inc

Advenchen Laboratories LLC

Affimed GmbH

Agency for Science, Technology and Research

Agenus Inc

Agilvax Inc

AIM ImmunoTech Inc

Akeso Inc

Alfasigma SpA

Alkermes Plc

Alligator Bioscience AB

Allinky Biopharma SL

Allist Shanghai Pharmaceutical Technology Co Ltd

Almac Discovery Ltd

AlphaMab Co Ltd

Alphamab Oncology

Alpine Immune Sciences Inc

Altimmune Inc

AltruBio Inc

ALX Oncology Inc

Amal Therapeutics SA

Amarin Corp Plc

amcure GmbH

Amgen Inc

AmMax Bio Inc

Ampo Biotechnology Inc

Amrita Therapeutics

Andes Biotechnologies

Anew Oncology Inc

Angex Pharmaceutical Inc

AnHeart Therapeutics Inc

Anwita Biosciences Inc

Apcegen Technologies Pvt Ltd

APEIRON Biologics AG

Apexian Pharmaceuticals Inc

Aphios Corp

Apogenix AG

Apollomics Inc

Apotex Inc

Aprogen Inc

Apros Therapeutics Inc

Araxes Pharma LLC

Arcus Biosciences Inc

Argonaut Therapeutics Ltd

AriBio

Arisaph Pharmaceuticals Inc

Arvinas Inc

Asana BioSciences LLC

Ascelia Pharma AB

Ascendis Pharma A/S

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Asclepiumm Taiwan Co Ltd

Aslan Pharmaceuticals Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atreca Inc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

B Cell Design SAS

Bantam Pharmaceutical LLC

Barricade Therapeutics Corp

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing BGI-GBI Biotech Co Ltd

Beijing Biostar Technologies Ltd

Beijing Eastern Biotech Co Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Beijing Luzhu Biotechnology Co Ltd

Beijing Mabworks Biotech Co Ltd

Benhealth Biopharmaceutical (Shenzhen) Co Ltd

Betta Pharmaceuticals Co Ltd

BeyondSpring Inc

Bicycle Therapeutics Plc

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

BioAtla LLC

BIOCND Inc

Biocon Ltd

BioCurity Pharmaceuticals Inc

BioEclipse Therapeutics Inc

BioIntegrator Ltd

BioLineRx Ltd

BioMed Valley Discoveries Inc

BiomX Inc

Bionomics Ltd

BioNTech SE

Biosceptre International Ltd

BioXcel Therapeutics Inc

BioXpress Therapeutics SA

bluebird bio Inc

Boehringer Ingelheim International GmbH

Bold Therapeutics Inc

Boston Biomedical Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Bromodomain Pharmaceuticals Inc

C4X Discovery Holdings Plc

Calithera Biosciences Inc

CanBas Co Ltd

Cancer Advances Inc

Cancer Prevention Pharmaceuticals Inc

Cancer Therapeutics Laboratories Inc

Canget BioTekpharma LLC

Cantargia AB

Cardiff Oncology Inc

Carna Biosciences Inc

CaroGen Corp

Carrick Therapeutics UK Ltd

CAS-Lamvac Biotech Co Ltd

CCRP Therapeutics GmbH

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellivery Therapeutics Inc

Cellix Bio Pvt Ltd

Cello Therapeutics Inc

Celltrion Inc

Celyad Oncology

Centus Biotherapeutics Ltd

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

ChemoCentryx Inc

Chengdu Huachuang Biotechnology Co Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Chi Cheung (Shanghai) Biomedical Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

ChoDang Pharm Co Ltd

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Cinnagen Co

Cipla BioTec Pvt Ltd

Cleveland BioLabs Inc

Cloaked Therapeutics LLC

COARE Biotechnology Inc

Coherent Biopharma

Compass Therapeutics LLC

Compugen Ltd

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Cue Biopharma Inc

Curamir Therapeutics Inc

Curegenix Inc

Cynvec LLC

Cytlimic Inc

Cytodyn Inc

CytoMed Therapeutics Pte Ltd

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals Inc

Decoy Biosystems Inc

Delta-Fly Pharma Inc

DevaCell Inc

Dicerna Pharmaceuticals Inc

Domain Therapeutics SA

Domainex Ltd

Dr. Reddy's Laboratories Ltd

Dragonboat Biopharmaceutical (Shanghai)Co Ltd

eFFECTOR Therapeutics Inc

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Elicio Therapeutics

EnGeneIC Ltd

Enochian Biosciences Inc

EntreChem SL

Enzene Biosciences Ltd

Enzo Biochem Inc

EpicentRx Inc

Epygen Biotech Pvt Ltd

Esperas Pharma Inc

Eternity Bioscience Inc

Etubics Corp

Euclises Pharmaceuticals Inc

Evelo Biosciences Inc

Evotec SE

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

FivePhusion Pty Ltd

Fog Pharmaceuticals Inc

Formosa Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Colorectal Cancer - Overview

Colorectal Cancer - Therapeutics Development

Colorectal Cancer - Therapeutics Assessment

Colorectal Cancer - Companies Involved in Therapeutics Development

Colorectal Cancer - Drug Profiles

Colorectal Cancer - Dormant Projects

Colorectal Cancer - Discontinued Products

Colorectal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Colorectal Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020

Colorectal Cancer – Pipeline by 3SBio Inc, H1 2020

Colorectal Cancer – Pipeline by 4D Pharma Plc, H1 2020

Colorectal Cancer – Pipeline by 4SC AG, H1 2020

Colorectal Cancer – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Colorectal Cancer – Pipeline by A2 Biotherapeutics Inc, H1 2020

Colorectal Cancer – Pipeline by Aadi Bioscience Inc, H1 2020

Colorectal Cancer – Pipeline by AB Science SA, H1 2020

Colorectal Cancer – Pipeline by AbbVie Inc, H1 2020

Colorectal Cancer – Pipeline by AbClon Inc, H1 2020

Colorectal Cancer – Pipeline by Abcuro Inc, H1 2020

Colorectal Cancer – Pipeline by ABM Therapeutics Inc, H1 2020

Colorectal Cancer – Pipeline by Abpro Corp, H1 2020

Colorectal Cancer – Pipeline by Aclaris Therapeutics Inc, H1 2020

Colorectal Cancer – Pipeline by Acrotech Biopharma LLC, H1 2020

Colorectal Cancer – Pipeline by Adamed Sp zoo, H1 2020

Colorectal Cancer – Pipeline by ADC Therapeutics SA, H1 2020

Colorectal Cancer – Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020

Colorectal Cancer – Pipeline by ADT Pharmaceuticals Inc, H1 2020

Colorectal Cancer – Pipeline by Aduro BioTech Inc, H1 2020

Colorectal Cancer – Pipeline by Advanced BioDesign, H1 2020

Colorectal Cancer – Pipeline by Advaxis Inc, H1 2020

Colorectal Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020

List of Figures

List of Figures

Number of Products under Development for Colorectal Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports